Edition:
United States

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.35USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,674
52-wk High
$2.65
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

VistaGen Therapeutics Reports Qtrly Loss Per Share $‍0.25​
Monday, 12 Feb 2018 04:30pm EST 

Feb 12 (Reuters) - VistaGen Therapeutics Inc ::VISTAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS.VISTAGEN THERAPEUTICS INC QTRLY LOSS PER SHARE $‍0.25​.VISTAGEN THERAPEUTICS INC - ‍AT DEC 31, HAD CASH, CASH EQUIVALENTS OF ABOUT $13.0 MILLION, COMPARED TO ABOUT $2.9 MILLION AT MARCH 31, 2017​.  Full Article

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
Wednesday, 3 Jan 2018 08:30am EST 

Jan 3 (Reuters) - Vistagen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​.  Full Article

Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
Wednesday, 20 Dec 2017 05:04pm EST 

Dec 20 (Reuters) - Intracoastal Capital Llc::REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>>: AS OF DEC 13 - SEC FILING.  Full Article

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 10:19am EST 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Wednesday, 18 Oct 2017 05:49pm EDT 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

Vistagen to buy up to 1.9 mln shares of common stock at $1.75 per share
Thursday, 31 Aug 2017 09:10am EDT 

Aug 31 (Reuters) - Vistagen Therapeutics Inc :Vistagen announces pricing of underwritten offering of common stock and warrants to purchase common stock.Vistagen Therapeutics Inc - ‍pricing of an underwritten public offering of 1.4 mlnshares of its common stock and warrants​.Vistagen Therapeutics Inc - to purchase up to 1.9 million shares of common stock at an offering price of $1.75 per share and related warrants​.Vistagen Therapeutics Inc - ‍gross proceeds of offering are expected to be approximately $2.4 million​.  Full Article

Vistagen Therapeutics' largest stockholder signs 6-month lock-up agreement
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Vistagen Therapeutics Inc :Vistagen Therapeutics' largest stockholder signs 6-month lock-up agreement.Vistagen Therapeutics - under agreement, stockholder and its affiliates agreed to not enter into any transaction involving co's securities during term of agreement.Vistagen Therapeutics - term of agreement runs through late-Oct. 2017 and covers about 36 pct of co's issued, outstanding equity securities on an as converted basis.  Full Article

Vistagen Therapeutics says European Patent Office has issued a notice of intention to grant company's European patent application for AV-101
Wednesday, 29 Mar 2017 09:00am EDT 

Vistagen Therapeutics Inc :Vistagen Therapeutics says European Patent Office (EPO) has issued a notice of intention to grant company's European patent application for AV-101.  Full Article

Vistagen Therapeutics provides business outlook
Thursday, 22 Sep 2016 08:05am EDT 

Vistagen Therapeutics Inc : Vistagen Therapeutics provides business outlook and sets corporate milestones . Says Vistagen expects to report topline data from its NIMH-sponsored Phase 2a study in Q2 of 2017 . Expects to receive FDA fast track designation for AV-101 as adjunctive treatment for MDD during first half of 2017. .Company anticipates topline results for AV-101 from Phase 2b study to be reported in Q3 of 2018.  Full Article